New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil [0.03%]
抗高血压的新治疗选择：评价阿利沙坦酯的潜在作用
Massimo Volpe,Carmine Savoia
Massimo Volpe
Renin-angiotensin-system (RAS) activation plays a key role in the development of hypertension and cardiovascular disease. Drugs that antagonize the RAS (angiotensin-converting enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]...
Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials [0.03%]
中老年高血压患者失眠应用缓释褪黑素疗效和安全性研究：多中心随机双盲安慰剂对照临床试验的联合分析
Patrick Lemoine,Alan G Wade,Amnon Katz et al.
Patrick Lemoine et al.
Background: Add-on prolonged-release melatonin (PRM) in antihypertensive therapy has been shown to ameliorate nocturnal hypertension. Hypertension is a major comorbidity among insomnia patients. The efficacy and safety of...
Alice J Owen,Christopher M Reid
Alice J Owen
Amlodipine is a long-acting, dihydropyridine calcium antagonist now widely used for lowering of elevated blood pressure. In recent years it has been shown to be effective in reducing both blood pressure and risk of cardiovascular (CV) event...
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination [0.03%]
奥美沙坦酯氢氯噻嗪联合治疗高血压的疗效及依据分析
Henry A Punzi
Henry A Punzi
Hypertension affects nearly one-third of all individuals in the US, yet one-half of all treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage of patients with uncontrolled BP is likely to be much highe...
Combining antihypertensive and antihyperlipidemic agents - optimizing cardiovascular risk factor management [0.03%]
降压药和降脂药的联合使用-优化心血管危险因素的管理
José Zamorano,Jonathan Edwards
José Zamorano
Clinical guidelines now recognize the importance of a multifactorial approach to managing cardiovascular (CV) risk. This idea was taken a step further with the concept of the Polypill™. There are, however, considerable patent, pharmacokine...
Gloria Valdés,Jenny Corthorn
Gloria Valdés
In primates, adequate growth of the fetus depends on the development of the uteroplacental unit. On the fetal side, this is achieved by the creation of the vascular network of the placenta. On the maternal side, the transformation of the sp...
Jennifer Frank,David Sommerfeld
Jennifer Frank
Resistant hypertension, defined as failure to achieve target blood pressure despite the use of optimal or maximum doses of at least 3 agents, one of which is a diuretic, or requiring 4 or more medications to achieve blood pressure goal, is ...
Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients [0.03%]
儿童患者的短期和长期生理及药理血压控制
Howard Trachtman
Howard Trachtman
The incidence of hypertension is rising in the general population. A parallel trend is present in children and adolescents. This reflects more intensive treatment and improved patient survival after a wide range of serious systemic illnesse...
Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension [0.03%]
固定复方替米沙坦-氨氯地平治疗高血压的临床应用价值
Julian Segura,Luis M Ruilope
Julian Segura
The majority of hypertensive patients, especially those with target organ damage, are likely to require multiple-drug therapy in order to reach blood pressure (BP) targets and reduce their risk of adverse vascular outcomes. The rationale fo...
Long-term use and tolerability of irbesartan for control of hypertension [0.03%]
长期应用厄贝沙坦治疗高血压的疗效及耐受性
Valentina Forni,Grégoire Wuerzner,Menno Pruijm et al.
Valentina Forni et al.
In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension. Irbesarta...